Skin acts as the first line of defense against pathogens and other harmful material from outside the body. Yet this barrier also excludes some beneficial drugs that could treat skin diseases. Now, researchers have taken the first steps in developing a chemotherapy for melanoma that can be “painted” directly on the skin, rather than injected or taken orally.
They report their results in ACS Nano.
According to the Skin Cancer Foundation, melanoma is the deadliest form of cancer because of its tendency to spread, or metastasize, from the skin to other parts of the body. Common treatments include surgery, radiation therapy and intravenous chemotherapy, but these can cause pain or unpleasant side effects. If scientists could find a way to administer chemotherapy through the skin, they could target the treatment directly to the tumor site and possibly avoid side effects. Bingfang He, Ran Mo and colleagues wanted to develop a gel that patients themselves could apply to a skin tumor. But first they had to figure out how to get the therapy to penetrate deep within the skin.
For this purpose, the researchers assembled nanoparticles called “transfersomes,” which consist of a phospholipid bilayer and surfactants that encapsulate drugs or other molecules — in this case, the chemotherapy drug paclitaxel. The surfactants made the particles more deformable so that they could better infiltrate the skin; these compounds also affected the lipid matrix of the skin to help the particles more easily pass. The researchers added a peptide to the surface of the transfersome to further help the particle penetrate the skin, as well as enter tumor cells. To increase the time that the transfersomes persisted on skin, the researchers embedded the nanoparticles into a hydrogel. Then, they painted the gel on tumors of melanoma-bearing mice once a day, in combination with intravenous administration of paclitaxel every other day. After 12 days, the tumors of these mice were about half the size of tumors in mice treated with intravenous paclitaxel alone, suggesting that the transfersome gel helped slow tumor growth.
The Latest on: Melanoma
via Google News
The Latest on: Melanoma
- Global Melanoma Detection Market Research with COVID-19 After Effects, Development Factors and Growth Analysis (2020-2026)on August 11, 2020 at 12:56 am
A recent report provides crucial insights along with application based and forecast information in the Global Melanoma Detection Market. The report provides a comprehensive analysis of key factors ...
- Dynamic control of tumor vasculature improves antitumor responses in a regional model of melanomaon August 6, 2020 at 2:14 am
Despite advances in therapy for melanoma, heterogeneous responses with limited durability represent a major gap in treatment outcomes. The purpose of this study was to determine whether alteration in ...
- Elios Therapeutics Personalized Cancer Vaccine Demonstrates Long-Term Survival Benefit Among High-Risk Melanoma Patients in Phase IIb Final Analysison August 5, 2020 at 4:15 am
Elios Therapeutics, a biopharmaceutical company developing innovative personalized therapeutic cancer vaccines, today announced final data from a prospective, randomized, double-blind, ...
- Popular blood pressure drug raises melanoma riskson August 4, 2020 at 9:06 pm
It has been linked to 20 per cent increased risk of malignant melanoma and a doubling of the risk of lip cancer. This year, more than 16,200 Australians will be diagnosed with a melanoma. The drug, ...
- An RNA vaccine for advanced melanomaon August 4, 2020 at 5:30 am
An RNA vaccine targeting tumour-associated antigens promotes T cell immunity in patients with advanced melanoma.
- Boston University researcher receives grant to fight melanomaon August 3, 2020 at 1:19 pm
Deborah Lang, MD, associate professor of dermatology at Boston University School of Medicine (BUSM), has been awarded a two-year, $250,000 grant from the Harry J. Lloyd Charitable Trust to further her ...
- Melanoma Research Alliance Hails FDA’s First ‘Triplet’ Combination Approval for Melanomaon August 3, 2020 at 1:16 pm
The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, welcomes the decision by the U.S. Food and Drug Administration (FDA) approving Genentech’s Tecentriq ...
- FDA Approves Triple Drug Combo for Melanomaon July 31, 2020 at 2:46 am
The triple-therapy combination of atezolizumab plus cobimetinib and vemurafenib is now approved for BRAF V600mutation-positive advanced melanoma.
- BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab) Combination in Melanomaon July 30, 2020 at 11:00 pm
BioNTech and Regeneron plan to jointly conduct a randomized Phase 2 study combining BNT111 FixVac and Libtayo for the treatment of melanoma that has progressed after prior PD-1 blockade -- Combines ...
via Bing News